Mechanisms of alterations in cardiac membrane Ca2+ transport due to excess catecholamines

被引:53
作者
Dhalla, KS
Rupp, H
Beamish, RE
Dhalla, NS
机构
[1] ST BONIFACE GEN HOSP,RES CTR,DIV CARDIOVASC SCI,WINNIPEG,MB R2H 2A6,CANADA
[2] UNIV MANITOBA,FAC MED,DEPT PHYSIOL,WINNIPEG,MB,CANADA
关键词
catecholamine-induced cardiotoxicity; cardiac Ca2+ transport; oxidative stress; cardiac membranes; intracellular Ca2+ overload;
D O I
10.1007/BF00120492
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The occurrence of excessive catecholamine release is often associated with stress due to the lifestyle of Western societies. Contrary to the general thinking that excess catecholamines produce cardiotoxicity mainly via binding to adrenoceptors, there is increasing evidence that catecholamine-induced deleterious actions may also occur through oxidative mechanisms. In this overview it is shown that a high dose of isoproterenol induces a biphasic change in cardiac Ca2+ transport in the sarcolemma and in sarcoplasmic reticulum. Both sarcolemmal and sarcoplasmic reticular Ca2+-transport activities are initially increased to maintain Ca2+ homeostasis and then are impaired, which may be associated with the occurrence of intracellular Ca2+ overload. On the other hand, mitochondrial Ca2+-transport activities exhibited a delayed increase. Pretreatment with vitamin E partially prevented the deleterious changes in cardiac membranes as well as the depressed energetic status of the heart muscle cell. It is concluded that excess catecholamines affect Ca2+-transport mechanisms primarily via oxidation reactions involving free radical-mediated damage. Thus drug approaches that reduce circulating catecholamines and/or prevent their oxidation should prove beneficial. A combination therapy involving inhibitors of catecholamine release, blockers of adrenoceptors, and antioxidants may be indicated for stress-induced heart disease.
引用
收藏
页码:231 / 238
页数:8
相关论文
共 24 条
[1]   MEASUREMENT OF ADRENOLUTIN AS AN OXIDATION-PRODUCT OF CATECHOLAMINES IN PLASMA [J].
DHALLA, KS ;
GANGULY, PK ;
RUPP, H ;
BEAMISH, RE ;
DHALLA, NS .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1989, 87 (01) :85-92
[2]  
Dhalla N S., 1992, Cardiovascular Toxicology, P239
[3]  
DHALLA NS, 1995, PHYSL PATHOPHYSIOLOG, P605
[4]  
DHALLA NS, 1987, PATHOGENESIS MYOCARD, P135
[5]  
DHALLA NS, 1983, MYOCARDIAL HYPERTROP, P527
[6]   A NOVEL MECHANISM OF ACTION FOR HYPERTENSION CONTROL - MOXONIDINE AS A SELECTIVE I-1-IMIDAZOLINE AGONIST [J].
ERNSBERGER, P ;
HAXHIU, MA ;
GRAFF, LM ;
COLLINS, LA ;
DRESHAJ, I ;
GROVE, DL ;
GRAVES, ME ;
SCHAFER, SG ;
CHRISTEN, MO .
CARDIOVASCULAR DRUGS AND THERAPY, 1994, 8 :27-41
[7]  
Fliegel L, 1985, Can J Cardiol, V1, P122
[8]   PHARMACODYNAMIC ACTION AND PHARMACOKINETICS OF MOXONIDINE AFTER SINGLE ORAL-ADMINISTRATION IN HYPERTENSIVE PATIENTS [J].
KIRCH, W ;
HUTT, HJ ;
PLANITZ, V .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (12) :1088-1095
[9]  
MAISCH B, 1992, POSTGRAD MED J, V68, pS11
[10]  
MAKINO N, 1985, Canadian Journal of Cardiology, V1, P225